Latest Naltrexone Stories
BETHESDA, Md., May 16, 2013 /PRNewswire/ -- TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows: Dear Shareholders, The board of directors of TNI BioTech, Inc. is very pleased to provide an update on the progress made over the last year....
MALVERN, Pa., May 10, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc. Endo presented FDA data collected from an ongoing epidemiology study that indicate that per 100,000 prescriptions dispensed, the past 30-day abuse rate of crush-resistant OPANA ER was 79 percent lower than the abuse rate of generic versions of...
The Coleman Institute was awarded the "Best of the Best" designation for excellence in Florida Addiction by Follow Media Consulting, Inc. Tampa, FL (PRWEB) May 09, 2013 The Coleman Institute was awarded the "Best of the Best" designation for excellence by Follow Media Consulting, Inc. in the category of Florida Addiction. This award signifies the continued commitment and dedication of the areas best in addiction rehabilitation and detoxification programs. The Coleman...
The Coleman Institute was awarded the "Best of the Best" designation for excellence in Addiction Treatment Seattle by Follow Media Consulting, Inc. Washington DC (PRWEB) April 13, 2013 The Coleman Institute was awarded the "Best of the Best" designation for excellence by Follow Media Consulting, Inc. in the category of Addiction Treatment Seattle. This award signifies the continued commitment and dedication of the areas best in rehab and detox services. Since 1998, the...
WASHINGTON, April 8, 2013 /PRNewswire/ -- EG Ministry of Health recently met with Dr. Gloria B. Herndon of GB Group Global in the nation's capital as part of Equatorial Guinea's efforts to drastically raise its standards of health care. These endeavors include building a pharmaceutical manufacturing facility in EG, implementing pharmaceutical quality control and policies, and exploring the release of a new treatment (Low Dose Naltrexone) against cancer and HIV/AIDS. The purpose of...
BETHESDA, Md., Feb. 1, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTCPINK: TNIB) has signed an exclusive licensing agreement for all of the intellectual property developed at Pennsylvania State by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer. The patents cover methods and formulations related to the treatment and prevention of cancers, particularly gastrointestinal cancer. More specifically, the present inventions describe the use of...
ALBANY, New York, January 9, 2013 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market [http://www.marketresearchreports.biz/analysis/158132 ] Leading business intelligence provider GBI Research [http://www.marketresearchreports.biz/publisher/2 ] has released its latest research report, entitled...
NEW YORK and BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB) announced today that it has signed an agreement for the acquisition of patent rights and orphan drug designation by the FDA to a novel late-stage drug, trademarked "LDN," for the treatment of Pediatric Crohn's Disease. TNI BioTech has signed a licensing agreement to acquire the exclusive patent rights for the intellectual property of Dr. Jill Smith and LDN Research LLC,...
Connie K. Ho for redOrbit.com – Your Universe Online You start off by kicking the smoking habit. Then you try to curb the hunger aches you have. For those who have suffered this situation in the past, researchers recently discovered a drug that can help ex-smoking women keep weight gain to a minimum. The study, conducted by the University of Chicago Medical Center, focused on naltrexone and is the first medication in a study that has shown to help women decrease weight gain a...
CHADDS FORD, Pa., Nov. 30, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has filed suit against the U.S. Food and Drug Administration (FDA) seeking a formal determination whether the original formulation of OPANA(® )ER (oxymorphone HCl) was voluntarily removed from the market in 2012 for reasons of safety involving the misuse of the drug; and FDA's immediate suspension of any abbreviated new drug...
